Title | Immunosurveillance in clinical cancer management. |
Publication Type | Journal Article |
Year of Publication | 2024 |
Authors | Kroemer G, Chan TA, Eggermont AMM, Galluzzi L |
Journal | CA Cancer J Clin |
Volume | 74 |
Issue | 2 |
Pagination | 187-202 |
Date Published | 2024 Mar-Apr |
ISSN | 1542-4863 |
Keywords | Antineoplastic Agents, Humans, Immunotherapy, Monitoring, Immunologic, Neoplasms |
Abstract | The progression of cancer involves a critical step in which malignant cells escape from control by the immune system. Antineoplastic agents are particularly efficient when they succeed in restoring such control (immunosurveillance) or at least establish an equilibrium state that slows down disease progression. This is true not only for immunotherapies, such as immune checkpoint inhibitors (ICIs), but also for conventional chemotherapy, targeted anticancer agents, and radiation therapy. Thus, therapeutics that stress and kill cancer cells while provoking a tumor-targeting immune response, referred to as immunogenic cell death, are particularly useful in combination with ICIs. Modern oncology regimens are increasingly using such combinations, which are referred to as chemoimmunotherapy, as well as combinations of multiple ICIs. However, the latter are generally associated with severe side effects compared with single-agent ICIs. Of note, the success of these combinatorial strategies against locally advanced or metastatic cancers is now spurring successful attempts to move them past the postoperative (adjuvant) setting to the preoperative (neoadjuvant) setting, even for patients with operable cancers. Here, the authors critically discuss the importance of immunosurveillance in modern clinical cancer management. |
DOI | 10.3322/caac.21818 |
Alternate Journal | CA Cancer J Clin |
PubMed ID | 37880100 |
PubMed Central ID | PMC10939974 |
Grant List | CA271915 / / National Institutes of Health/National Cancer Institute / CA274291 / / National Institutes of Health/National Cancer Institute / CA232097 / / National Institutes of Health/National Cancer Institute / CA205426 / / National Institutes of Health/National Cancer Institute / CA274513 / / National Institutes of Health/National Cancer Institute / BC180476P1 / / US Department of Defense / BC210945 / / US Department of Defense / W81XWH2120034 / / US Department of Defense / I16-0064 / / STARR Cancer Consortium / / / Ligue Contre le Cancer / / / Agence National de la Recherche / / / Association pour la Recherche sur le Cancer / / / Fondation pour la Recherche Médicale / ERC-2021-ADG / / European Research Council Advanced Investigator Award / 101052444 / / European Research Council Advanced Investigator Award / / / Crimson; Institut National du Cancer / / / LabEx Immuno-Oncology / / / Cancer Research ASPIRE Award from the Mark Foundation / / / US Food and Drug Administration / |